Developer docs
API playgroundTry for free, no card

Search company profiles

Beeline Medicines

Full company profile

uuid00vqjyg

Namestring
Beeline Medicines
Legal namestring
Beeline Medicines Corporation
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Beeline Medicines is a clinical-stage biotechnology company developing precision immunology therapies for autoimmune and inflammatory diseases. Founded in July 2025 through a partnership between Bristol Myers Squibb and Bain Capital Life Sciences, the company officially launched from stealth in April 2026 with a $300 million Series A financing led by Bain Capital Life Sciences with participation from CPP Investments. It is headquartered in Boston, Massachusetts with an additional operational presence in Stamford, Connecticut, and operates with 11-50 employees. The company's pipeline consists of five immunology programs licensed from Bristol Myers Squibb: afimetoran (an oral TLR7/8 inhibitor in Phase 2 for systemic lupus erythematosus with FDA Fast Track designation), BLN-326 (a long-acting IL-2-CD25 fusion protein in Phase 1b for atopic dermatitis and lupus), lomedeucitinib (a next-generation allosteric TYK2 inhibitor that completed a Phase 2 psoriasis trial), BLN-481 (a selective anti-IL-18Rb antibody with a planned Phase 1 study), and BLN-498 (a myeloid-selective IL-10 therapeutic in preclinical development).

The company's underlying technology centers on mechanistically-informed precision immunology, using small molecule inhibitors and biologic therapeutics to target validated upstream drivers of immune dysregulation (endosomal TLRs, TYK2 signaling, IL-18 receptor beta) and to rebalance Treg/effector and pro-/anti-inflammatory axes, with the goal of restoring immune homeostasis rather than broadly suppressing immunity. Several assets are positioned as first-in-class or best-in-class within their respective mechanism classes, and the oral, once-daily dosing of the small molecule programs is highlighted as a differentiator.

Beeline Medicines is pre-revenue and has not disclosed pricing for future commercial products. Its business model anticipates revenue generation through the future commercialization of approved therapeutics via pharmaceutical wholesale and specialty pharmacy distribution channels, targeting rheumatologists, dermatologists, and other specialists treating patients with lupus, atopic dermatitis, psoriasis, and other immune-mediated conditions. Until regulatory approval, the company is funded by its $300M Series A and operates as a clinical development organization with enterprise go-to-market characteristics rather than a commercial sales operation.

Short descriptiontext

Beeline Medicines is a Boston-based, clinical-stage biotechnology company developing precision immunology therapies for autoimmune and inflammatory diseases, with a five-program pipeline (including lead asset afimetoran for lupus) licensed from Bristol Myers Squibb and funded by a $300M Bain Capital-led Series A.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersStamford, United States
HQ citystring
Stamford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision immunology therapeutics, autoimmune disease drug development, small molecule inhibitors, biologic immunotherapy pipeline, clinical-stage biotechnology
Industry1 code
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Autoimmune and Inflammatory Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. The company is developing a pipeline of five immunology programs licensed from Bristol Myers Squibb. Revenue will be generated through commercialization of approved therapeutics for autoimmune and inflammatory diseases once clinical development is completed and regulatory approvals are obtained.

beelinemedicines.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Beeline Medicines is a clinical-stage biotechnology company developing a pipeline of five precision immunology therapies — small molecule inhibitors and biologic therapeutics — licensed from Bristol Myers Squibb. The portfolio targets validated pathways of immune dysfunction in autoimmune and inflammatory diseases, with lead program afimetoran (TLR7/8 inhibitor) advancing in Phase 2 for systemic lupus erythematosus under FDA Fast Track designation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 2 trial completion expected in second half of 2026 for afimetoran in SLE
+1 more record
Product overview1 text field

Beeline Medicines is a clinical-stage biotechnology company developing a pipeline of five precision immunology therapies licensed from Bristol Myers Squibb for autoimmune and inflammatory diseases. The portfolio includes Afimetoran (oral TLR7/8 inhibitor for lupus), BLN-326 (IL-2-CD25 fusion protein for atopic dermatitis/lupus), Lomedeucitinib (TYK2 inhibitor), BLN-481 (anti-IL-18Rb antibody), and BLN-498 (myeloid-selective IL-10). The company's mechanistically-informed approach targets underlying causes of immune-mediated diseases with the goal of restoring immune balance and delivering transformative impact for patients.

Product and service5 records
1Afimetoran
CategoryClinical Program (Late Clinical)
Description

Selective, oral, once-daily equipotent small molecule inhibitor of TLR7 and TLR8 for lupus treatment, blocking endosomal immune receptors that drive type I interferon production, pro-inflammatory cytokine release, and downstream autoantibody generation. Lead indication is systemic lupus erythematosus (SLE).

2BLN-326 (formerly BMS-986326)
CategoryClinical Program (Early Clinical)
Description

Novel, long-acting IL-2-CD25 fusion protein biologic designed to slowly release IL-2 and selectively expand FOXP3+ regulatory T cells for inflammatory diseases. In development for atopic dermatitis and lupus.

3Lomedeucitinib (formerly BMS-986322)
CategoryClinical Program (Late Clinical)
Description

Oral, next-generation, allosteric small molecule TYK2 inhibitor with enhanced selectivity and no functional activity against JAK1/2/3. Demonstrated compelling clinical activity in a Phase 2 psoriasis trial with planned development in multiple autoimmune and inflammatory conditions.

4BLN-481 (formerly BMS-986481)
CategoryEmerging Pipeline (Preclinical)
Description

First and only therapeutic antibody designed to selectively antagonize IL-18 receptor beta (IL-18Rb), providing a receptor-specific approach to blocking IL-18-driven inflammation while preserving homeostatic functions. In preclinical/early clinical development.

5BLN-498 (formerly BMS-986498)
CategoryPreclinical Program
Description

Potentially first-in-class myeloid-selective IL-10 therapeutic engineered to harness anti-inflammatory and tolerance-promoting effects while avoiding T-cell-driven IFN-gamma activation and hematologic toxicities seen with non-selective IL-10 therapies. In preclinical development.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Bristol Myers Squibb
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-07-01
Description

Beeline Medicines licensed five immunology and inflammation drug candidates from Bristol Myers Squibb as the foundation of its pipeline. The programs include afimetoran (TLR7/8 inhibitor), BLN-326 (IL-2-CD25 fusion protein), lomedeucitinib (TYK2 inhibitor), BLN-481 (Anti-IL-18Rb antibody), and BLN-498 (Myeloid-selective IL-10). The company was originally formed in July 2025 through this partnership. Bristol Myers Squibb's Chief Research Officer, Dr. Robert Plenge, serves on Beeline Medicines' Board of Directors.

beelinemedicines.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large pharma with Olumiant (baricitinib) approved in lupus and other autoimmune indications and a deep immunology pipeline; comparable broad incumbent setting competitive benchmarks in Beeline's target indications.

TypeDirect peer
Description

Late-stage immunology biotech with approved FcRn antagonist Vyvgart (efgartigimod) for autoimmune indications; directly comparable as a focused, clinical-stage-to-commercial immunology company executing a multi-indication precision-immunology strategy.

TypeBroad incumbent
Description

Global pharma co-developing Dupixent (dupilumab) with Regeneron, the dominant atopic dermatitis therapy; directly relevant incumbent competitor to BLN-326 in atopic dermatitis and to Beeline's broader IL-pathway programs.

TypeBroad incumbent
Description

Large immunology incumbent with leading franchises Skyrizi and Rinvoq across psoriatic and rheumatologic diseases; comparable broad incumbent defining the standard-of-care landscape Beeline's TYK2 and IL-2 programs must compete against.

TypeDirect peer
Description

Clinical-stage immunology company developing nanobody-based therapies for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis; comparable as a focused, asset-centric inflammation biotech pursuing differentiated biologics.

TypeDirect peer
Description

Pre-commercial immunology biotech developing engineered protein therapies for autoimmune and inflammatory diseases (acquired by Vertex for ~$4.9B in 2024); directly comparable precision-immunology peer with a similar small-molecule-and-biologic pipeline profile.

7Bristol Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical company that originated Beeline's pipeline and markets Sotyktu (TYK2 inhibitor) and Saphnelo (lupus); key licensor, board participant, and the most direct incumbent competitor in Beeline's target indications.

TypeDirect peer
Description

Clinical-stage biotech developing targeted protein degraders for immunology and inflammation indications; comparable as a platform-based immunology company advancing novel mechanisms into autoimmune disease trials.

TypeDirect peer
Description

Clinical-stage immunology-focused biotech developing antibodies for inflammatory and autoimmune diseases; comparable peer pursuing similar mechanism-driven, indication-targeted development in rheumatology and dermatology.

TypeEmerging player
Description

Mid-to-late-stage biotech that entered autoimmune disease via the Alpine Immune Sciences acquisition and is advancing selective immunology assets; comparable as a recently expanded immunology platform with a similar precision-mechanism thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Beeline Medicines

Autoimmune and Inflammatory Disease Therapeuticsbeelinemedicines.com

Beeline Medicines is a Boston-based, clinical-stage biotechnology company developing precision immunology therapies for autoimmune and inflammatory diseases, with a five-program pipeline (including lead asset afimetoran for lupus) licensed from Bristol Myers Squibb and funded by a $300M Bain Capital-led Series A.

What Beeline Medicines does

Beeline Medicines is a clinical-stage biotechnology company developing precision immunology therapies for autoimmune and inflammatory diseases. Founded in July 2025 through a partnership between Bristol Myers Squibb and Bain Capital Life Sciences, the company officially launched from stealth in April 2026 with a $300 million Series A financing led by Bain Capital Life Sciences with participation from CPP Investments. It is headquartered in Boston, Massachusetts with an additional operational presence in Stamford, Connecticut, and operates with 11-50 employees. The company's pipeline consists of five immunology programs licensed from Bristol Myers Squibb: afimetoran (an oral TLR7/8 inhibitor in Phase 2 for systemic lupus erythematosus with FDA Fast Track designation), BLN-326 (a long-acting IL-2-CD25 fusion protein in Phase 1b for atopic dermatitis and lupus), lomedeucitinib (a next-generation allosteric TYK2 inhibitor that completed a Phase 2 psoriasis trial), BLN-481 (a selective anti-IL-18Rb antibody with a planned Phase 1 study), and BLN-498 (a myeloid-selective IL-10 therapeutic in preclinical development).

The company's underlying technology centers on mechanistically-informed precision immunology, using small molecule inhibitors and biologic therapeutics to target validated upstream drivers of immune dysregulation (endosomal TLRs, TYK2 signaling, IL-18 receptor beta) and to rebalance Treg/effector and pro-/anti-inflammatory axes, with the goal of restoring immune homeostasis rather than broadly suppressing immunity. Several assets are positioned as first-in-class or best-in-class within their respective mechanism classes, and the oral, once-daily dosing of the small molecule programs is highlighted as a differentiator.

Beeline Medicines is pre-revenue and has not disclosed pricing for future commercial products. Its business model anticipates revenue generation through the future commercialization of approved therapeutics via pharmaceutical wholesale and specialty pharmacy distribution channels, targeting rheumatologists, dermatologists, and other specialists treating patients with lupus, atopic dermatitis, psoriasis, and other immune-mediated conditions. Until regulatory approval, the company is funded by its $300M Series A and operates as a clinical development organization with enterprise go-to-market characteristics rather than a commercial sales operation.

Beeline Medicines firmographics

Firmographics
Name
Beeline Medicines
Legal name
Beeline Medicines Corporation
Website
https://beelinemedicines.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
51–100 employees
Short description
Beeline Medicines is a Boston-based, clinical-stage biotechnology company developing precision immunology therapies for autoimmune and inflammatory diseases, with a five-program pipeline (including lead asset afimetoran for lupus) licensed from Bristol Myers Squibb and funded by a $300M Bain Capital-led Series A.
Ownership category
akta.pro rank

Beeline Medicines industry classification

Industry
Product category
Autoimmune and Inflammatory Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Precision immunology therapeutics
  • Autoimmune disease drug development
  • Small molecule inhibitors
  • Biologic immunotherapy pipeline
  • Clinical-stage biotechnology

Where Beeline Medicines is headquartered

Location

Headquarters

HQ city
Stamford
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Beeline Medicines business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical product sales: Pre-revenue clinical-stage biotech company. The company is developing a pipeline of five immunology programs licensed from Bristol Myers Squibb. Revenue will be generated through commercialization of approved therapeutics for autoimmune and inflammatory diseases once clinical development is completed and regulatory approvals are obtained.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Beeline Medicines product offering

Product offering

Core offering

Beeline Medicines is a clinical-stage biotechnology company developing a pipeline of five precision immunology therapies — small molecule inhibitors and biologic therapeutics — licensed from Bristol Myers Squibb. The portfolio targets validated pathways of immune dysfunction in autoimmune and inflammatory diseases, with lead program afimetoran (TLR7/8 inhibitor) advancing in Phase 2 for systemic lupus erythematosus under FDA Fast Track designation.

Product overview

Beeline Medicines is a clinical-stage biotechnology company developing a pipeline of five precision immunology therapies licensed from Bristol Myers Squibb for autoimmune and inflammatory diseases. The portfolio includes Afimetoran (oral TLR7/8 inhibitor for lupus), BLN-326 (IL-2-CD25 fusion protein for atopic dermatitis/lupus), Lomedeucitinib (TYK2 inhibitor), BLN-481 (anti-IL-18Rb antibody), and BLN-498 (myeloid-selective IL-10). The company's mechanistically-informed approach targets underlying causes of immune-mediated diseases with the goal of restoring immune balance and delivering transformative impact for patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Afimetoran Selective, oral, once-daily equipotent small molecule inhibitor of TLR7 and TLR8 for lupus treatment, blocking endosomal immune receptors that drive type I interferon production, pro-inflammatory cytokine release, and downstream autoantibody generation. Lead indication is systemic lupus erythematosus (SLE).
  • BLN-326 (formerly BMS-986326) Novel, long-acting IL-2-CD25 fusion protein biologic designed to slowly release IL-2 and selectively expand FOXP3+ regulatory T cells for inflammatory diseases. In development for atopic dermatitis and lupus.
  • Lomedeucitinib (formerly BMS-986322) Oral, next-generation, allosteric small molecule TYK2 inhibitor with enhanced selectivity and no functional activity against JAK1/2/3. Demonstrated compelling clinical activity in a Phase 2 psoriasis trial with planned development in multiple autoimmune and inflammatory conditions.
  • BLN-481 (formerly BMS-986481) First and only therapeutic antibody designed to selectively antagonize IL-18 receptor beta (IL-18Rb), providing a receptor-specific approach to blocking IL-18-driven inflammation while preserving homeostatic functions. In preclinical/early clinical development.
  • BLN-498 (formerly BMS-986498) Potentially first-in-class myeloid-selective IL-10 therapeutic engineered to harness anti-inflammatory and tolerance-promoting effects while avoiding T-cell-driven IFN-gamma activation and hematologic toxicities seen with non-selective IL-10 therapies. In preclinical development.

Quantifiable outcome

  • Phase 2 trial completion expected in second half of 2026 for afimetoran in SLE
  • +1 more outcomes

Companies that use Beeline Medicines

Customer profile

Segments2 records

Ideal customer profiles3 records

Beeline Medicines technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Beeline Medicines partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Bristol Myers SquibbcoreOEM/ Whitelabel/ Licensing Partner · 1 July 2025Beeline Medicines licensed five immunology and inflammation drug candidates from Bristol Myers Squibb as the foundation of its pipeline. The programs include afimetoran (TLR7/8 inhibitor), BLN-326 (IL-2-CD25 fusion protein), lomedeucitinib (TYK2 inhibitor), BLN-481 (Anti-IL-18Rb antibody), and BLN-498 (Myeloid-selective IL-10). The company was originally formed in July 2025 through this partnership. Bristol Myers Squibb's Chief Research Officer, Dr. Robert Plenge, serves on Beeline Medicines' Board of Directors.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Beeline Medicines competitors and assessment

Company assessment

Broad incumbents

  • Eli Lilly: Large pharma with Olumiant (baricitinib) approved in lupus and other autoimmune indications and a deep immunology pipeline; comparable broad incumbent setting competitive benchmarks in Beeline's target indications.
  • Sanofi: Global pharma co-developing Dupixent (dupilumab) with Regeneron, the dominant atopic dermatitis therapy; directly relevant incumbent competitor to BLN-326 in atopic dermatitis and to Beeline's broader IL-pathway programs.
  • AbbVie: Large immunology incumbent with leading franchises Skyrizi and Rinvoq across psoriatic and rheumatologic diseases; comparable broad incumbent defining the standard-of-care landscape Beeline's TYK2 and IL-2 programs must compete against.
  • Bristol Myers Squibb: Large pharmaceutical company that originated Beeline's pipeline and markets Sotyktu (TYK2 inhibitor) and Saphnelo (lupus); key licensor, board participant, and the most direct incumbent competitor in Beeline's target indications.

Direct peers

  • Argenx: Late-stage immunology biotech with approved FcRn antagonist Vyvgart (efgartigimod) for autoimmune indications; directly comparable as a focused, clinical-stage-to-commercial immunology company executing a multi-indication precision-immunology strategy.
  • MoonLake Immunotherapeutics: Clinical-stage immunology company developing nanobody-based therapies for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis; comparable as a focused, asset-centric inflammation biotech pursuing differentiated biologics.
  • Alpine Immune Sciences: Pre-commercial immunology biotech developing engineered protein therapies for autoimmune and inflammatory diseases (acquired by Vertex for ~$4.9B in 2024); directly comparable precision-immunology peer with a similar small-molecule-and-biologic pipeline profile.
  • Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders for immunology and inflammation indications; comparable as a platform-based immunology company advancing novel mechanisms into autoimmune disease trials.
  • AnaptysBio: Clinical-stage immunology-focused biotech developing antibodies for inflammatory and autoimmune diseases; comparable peer pursuing similar mechanism-driven, indication-targeted development in rheumatology and dermatology.

Emerging players

  • Vertex Pharmaceuticals: Mid-to-late-stage biotech that entered autoimmune disease via the Alpine Immune Sciences acquisition and is advancing selective immunology assets; comparable as a recently expanded immunology platform with a similar precision-mechanism thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Beeline Medicines social profiles

Digital presence

Beeline Medicines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Beeline Medicines leadership team

Management profile

Number of profiles

Profiles11 records

Beeline Medicines funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Beeline Medicines M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beeline Medicines

What does Beeline Medicines do?

Beeline Medicines is a clinical-stage biotechnology company developing a pipeline of five precision immunology therapies — small molecule inhibitors and biologic therapeutics — licensed from Bristol Myers Squibb. The portfolio targets validated pathways of immune dysfunction in autoimmune and inflammatory diseases, with lead program afimetoran (TLR7/8 inhibitor) advancing in Phase 2 for systemic lupus erythematosus under FDA Fast Track designation.

Is Beeline Medicines a public or private company?

Beeline Medicines is a private company. It is classified as venture growth investor backed and is currently operating.

When was Beeline Medicines founded?

Beeline Medicines was founded in 2025. It employs 51 to 100 people.

Where is Beeline Medicines based?

Beeline Medicines is headquartered in Stamford, United States, in the North America region.

How does Beeline Medicines make money?

One revenue line is on record: pharmaceutical product sales.

Who are Beeline Medicines's main competitors?

Broad incumbents on record are Eli Lilly, Sanofi, AbbVie and Bristol Myers Squibb. Direct peers are Argenx, MoonLake Immunotherapeutics, Alpine Immune Sciences, Kymera Therapeutics and AnaptysBio. Vertex Pharmaceuticals is listed as an emerging player.

Does Beeline Medicines have an API?

No public API is recorded for Beeline Medicines.

What industry is Beeline Medicines in?

Beeline Medicines's product category is Autoimmune and Inflammatory Disease Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooBeeline Medicines’ BMS-licensed drug shows benefit in Phase II lupus trialBeeline Medicines reported that its BMS-licensed drug afimetoran showed statistically significant benefit at all three doses in a Phase II lupus trial, with SRI-4 response rates of 67.8%, 64.1%, and 66.1% versus 34.4% for placebo. The company plans to advance afimetoran into Phase III development in 2027.The Pharma LetterBeeline plans Phase III lupus trial after afimetoran resultsBeeline Medicines plans to begin Phase III development of afimetoran in systemic lupus erythematosus in 2027. Phase II results showed all three tested doses improved response rates versus placebo. The oral treatment inhibits Toll-like receptors 7 and 8.Business & FinancialBeeline Medicines Announces Presentation Of Phase 2 Results Of Afimetoran In Systemic Lupus Erythematosus At ACR Convergence 2026Beeline Medicines presented Phase 2 results of afimetoran in systemic lupus erythematosus at ACR Convergence 2026. All three doses showed SRI-4 response rates of 64-67% versus 34% for placebo, with consistent secondary endpoint improvements and well-tolerated safety. The company plans Phase 3 development in 2027.Clinical Trials ArenaBeeline Medicines’ Phase II SLE trial of afimetoran meets primary endpointBeeline Medicines' Phase II trial of afimetoran in active moderate-to-severe SLE met its primary endpoint, with all three doses showing higher SRI-4 response rates at week 48 versus placebo (p<0.001). The 248-patient trial also reported consistent secondary improvements and a safety profile in line with Phase I. Further details will be presented at an upcoming medical congress.FierceBiotechBeeline flies into phase 3 as oral lupus drug soars past placeboBeeline Medicines' afimetoran met its primary endpoint in a phase 2 trial for systemic lupus erythematosus, showing higher SRI-4 response rates than placebo after 48 weeks. The company plans to advance the drug into pivotal development in SLE and cutaneous lupus, with Merck KGaA claiming first-in-class status for a similar TLR7/8 inhibitor.Phirda融资21亿元:礼来为何押注这家核药公司?In July, biotech financing totaled $166.5M across 15 deals, with nuclear medicine and AI drug discovery leading. LEO Pharma backed AdvanCell's $315M D-round, expanding its partnership for alpha-particle therapies. Other notable rounds included Chai Discovery's $400M C-round and Celea's $100M funding.NewswireCPP Investments Net Assets Total $863.6 Billion at First Quarter Fiscal 2027CPP Investments reported net assets of $863.6 billion at the end of its first quarter of fiscal 2027, up $70.3 billion from the prior quarter. The increase included $60.2 billion in net income and $10.1 billion in net transfers from the Canada Pension Plan, with a quarterly net return of 7.5% and a 10-year annualized return of 9.4%.Pulse 2.0Beeline Medicines Raises $426.3 Million Series A To Advance Autoimmune And Inflammatory Disease PortfolioBeeline Medicines announced a $126.3 million Series A extension, bringing its total Series A financing to $426.3 million, with participation from existing investors Bain Capital, Canada Pension Plan Investment Board, and Bristol Myers Squibb. The clinical-stage biotechnology company will use the proceeds to advance its immunology portfolio, including pivotal development of lead program afimetoran for lupus, with a Phase 2 readout expected in the second half of 2026. Over the next 12 months, Beeline also plans to initiate additional clinical trials across its pipeline of selective therapeutic candidates targeting immune-mediated diseases.VC News DailyBeeline Medicines Inks Upsized Series A of $426.3MBeeline Medicines Corporation, a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases, announced the closing of a $126.3 million Series A extension, bringing its total Series A financing to $426.3 million. The funding was provided by existing shareholders and investors including Bain Capital, Canada Pension Plan Investment Board, and Bristol Myers Squibb. The proceeds will support the initiation of several clinical studies across the Company's immunology portfolio, including planned pivotal development of its lead program afimetoran in lupus.BioSpace5 largest VC rounds of H1 2026In the first half of 2026, biopharma venture capital funding showed a "selective recovery," with $2.1 billion flowing to Isomorphic Labs—the second-largest biotech round ever—in May via a Series B led by investors betting on AI-driven drug discovery. Four other large raises followed: NewLimit ($435M Series C for epigenome reprogramming), Beeline Medicines ($426.3M Series A for immunology including assets from Bristol Myers Squibb), Parabilis Medicines ($305M Series F for a cancer peptide therapy, later followed by a record $670M IPO), and Corxel Pharmaceuticals ($287M Series D1 for a GLP-1 obesity drug). The overall trend reflects capital becoming more discerning, concentrating in later-stage, de-risked assets with near-term clinical catalysts while early-stage financing remains near its lowest annual count since before the pandemic.